Malick Gibani is a Clinical Lecturer and Specialist Registrar in Infectious Diseases and Medical Microbiology. He completed his basic medical training at the University of Oxford, after which he continued his training in general medicine in London. He later joined the Oxford Vaccine Group in the Dept of Paediatrics, University of Oxford, where he undertook a DPhil with Andrew Pollard and Christine Rollier, focussing on the application of human challenge models to better understand pathogenesis and immunity to Salmonella Typhi and Paratyphi A. He has worked on a range of clinical vaccine trials including for Ebola, RSV and meningococcal disease.
Since 2019, he has worked as a clinical lecturer in the Department for Infectious Disease at Imperial College London. His research interests focus on the development of controlled human infection models and their application to accelerate vaccines for enteric diseases.
et al., 2022, The clinical presentation of monkeypox: a retrospective case-control study of patients with possible or probable monkeypox in a West London cohort, International Journal of Infectious Diseases, ISSN:1201-9712
RECOVERY Collaborative Group, 2022, Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis., The Lancet, Vol:400, ISSN:0140-6736, Pages:359-368
et al., 2022, Cohorting inpatients with Omicron and Delta variants of Sars-CoV-2 does not increase rates of mixed infection, Journal of Infection, Vol:85, ISSN:0163-4453, Pages:e18-e20
et al., 2022, Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers, Infection and Immunity, Vol:90, ISSN:0019-9567
Gibani MM, 2022, Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines, Lancet Infectious Diseases, Vol:22, ISSN:1473-3099, Pages:435-436